Michelle Chern is a corporate associate in the Bay Area offices of Latham & Watkins and is a member of the firm’s Emerging Companies & Growth Practice.

Ms. Chern represents emerging companies and venture capital firms in various corporate transactions.

 Her experience includes:

  • Venture capital financings
  • Formation and startup matters
  • General corporate representation

She advises clients on a variety of transactions within the technology and life sciences industries.

As part of her active pro bono practice, Ms. Chern has represented individuals seeking asylum. She has also counseled clients in housing discrimination cases.

Ms. Chern's experience includes representing:

  • Kobold Metals in its US$192.5 million Series B financing
  • NewLimit in its US$40 million Series A financing
  • Sonoma Biotherapeutics in its strategic collaboration with Regeneron Pharmaceuticals
  • Medallion in its US$35 million Series C financing
  • Avenir as lead investor in the US$111 million Series B financing by Xepelin
  • Clarify Health in its US$150 million Series D financing
  • OpenSea in its US$300 million Series C financing

Bar Qualification

  • California
  • New York


  • JD, New York University School of Law, 2019
  • BA, University of California, Berkeley, 2013